Monovalent modified mRNA influenza vaccine encoding influenza hemagglutinin with lipid nanoparticles (LNP)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Monovalent modified mRNA influenza vaccine encoding influenza hemagglutinin with lipid nanoparticles (LNP), covering 2025-09-12 to 2025-09-12. Get the full timeline:
Most recent: Clinical Trial Update: Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above [Phase 1]